**Lateral compression type-1 fracture fixation in the elderly (L1FE).**

**Study Protocol for a randomised controlled trial (with internal pilot) comparing the effects of INFIX surgery and non-surgical management for treating patients with Lateral Compression type-1 (LC-1) fragility fractures.**

Elizabeth Cook#

Joanne Laycock

Mehool Acharya

Michael Ross Backhouse

Belen Corbacho

Laura Doherty

Daren Forward

Catherine Hewitt

Catherine Hilton

Peter Hull

Jamila Kassam

Camila Maturana

Catriona Mcdaid

Jenny Roche

Dhanupriya Sivapathasuntharam

David Torgerson

Peter Bates

# Corresponding author (email: liz.cook@york.ac.uk)

**Abstract**

**Background:** Lateral compression type-1 (LC-1) fragility fractures are a common, painful injury in older adults resulting in reduced mobility. The incidence of these fractures is increasing with the growing older adult population. Current standard of care is non-surgical management, however patients with this injury are at risk of long term immobility and the related complications. INFIX is a pelvic fixation device used in younger patients with high energy fractures. The device is fitted via a percutaneous technique with no external pin sites and has good purchase even in osteoporotic bone. It therefore has the potential to be well tolerated in patients with LC-1 fragility fractures. INFIX could improve patients’ ability to mobilise and reduce the risk of immobility related complications. However, there is a risk of complications related to surgery and robust evidence is required on patient outcomes. This study will investigate the clinical and cost effectiveness of surgical fixation with INFIX compared to non-surgical management of LC-1 fragility fractures in older adults.

**Methods**: A multi-centre randomised controlled trial of 600 patients allocated 1:1 to non-surgical management or INFIX surgery. The study will have a 12-month internal pilot to assess recruitment and trial feasibility. The primary outcome will be patient quality of life over 6 months, measured by the patient reported EQ-5D-5L. Secondary outcomes will include physical function, mental health, pain, delirium, imaging assessment, resource use and complications.

**Discussion:** The L1FE study aims to compare the clinical and cost effectiveness of surgical and non-surgical management of people aged 60 years and older with LC-1 fragility fractures. The trial is sufficiently powered and rigorously designed to inform future clinical and patient decision making and allocation of NHS resources.

**Trial Registration:** Trial Identifier: ISRCTN16478561. Registry Name: International Standard Randomised Controlled Trial Number Registry. Registered: 8th April 2019

**Keywords:** INFIX surgery, Lateral compression type-1, LC-1, pelvic fracture fixation, elderly patients, older adults, fragility fracture, osteoporotic bone, pubic ramus fracture, immobility-related complications

|  |  |
| --- | --- |
| Title | Lateral compression type-1 fracture fixation in the elderly (L1FE). Protocol for a randomised controlled trial (with internal pilot) comparing the effects of INFIX surgery and non-surgical management for treating people with Lateral Compression type-1 (LC-1) fragility fractures. |
| Trial registration | Trial Identifier: ISRCTN16478561Registry Name: International Standard Randomised Controlled Trial Number RegistryRegistered: 8th April 2019<https://www.isrctn.com/ISRCTN16478561?q=ISRCTN16478561&filters=&sort=&offset=1&totalResults=1&page=1&pageSize=10&searchType=basic-search>  |
| Protocol version | Protocol V3.2 22nd December 2020 |
| Funding | The National Institute for Health Research Health Technology Assessment programme (reference number: 16/167/57) |
| Author details | E Cook\*J Laycock\*M Acharya\*\*\*M R Backhouse\* & \*\*\*\*\*\*B Corbacho\*L Doherty\*D Forward\*\*\*\*C Hewitt\*C Hilton\*\*P Hull\*\*\*\*\*J Kassam\*\*C Maturana\*C Mcdaid\*J Roche\*D Sivapathasuntharam\*\*D Torgerson\*P Bates\*\*\*York Trials Unit, Department of Health Sciences, University of York, Heslington, YO10 5DD\*\*Bart’s Health NHS Trust, The Royal London Hospital, Whitechapel Road, Whitechapel, London, E1 1BB\*\*\*Pelvic and Acetabular Reconstruction Unit. Southmead Hospital Bristol. BS10 5NB\*\*\*\* Nottingham University Hospitals, Derby Road, Nottingham NG7 2UH\*\*\*\*\* Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ\*\*\*\*\*\*current affiliation Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, CV4 7AL, (work undertaken at \*).  |
| Name and contact information for the trial sponsor | Sponsor: Bart’s Health NHS Trust Contact: Dr Mays Jawad, Research & Development Governance Operations Manager, Joint Research Management Office, Queen Mary Innovation Centre, Lower Ground Floor, 5 Walden Street, London, E1 2EF. Telephone: 02078827275. Email: research.governance@qmul.ac.uk  |
| Role of sponsor | The sponsor played no part in study design; and will play no part in the collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication. |

**Background**

**Research Question:** What is the clinical and cost effectiveness of surgical fixation with INFIX compared to non-surgical management of Lateral compression type-1 (LC-1) fragility fractures in older adults?

**What are LC-1 fractures and how prevalent are they?**

LC-1 fractures are a common fragility fracture in older adults, especially those with osteoporosis. They typically involve a fracture of the pubic ramus, which is perceived by the patient as groin pain when they mobilise. There is usually also a ‘buckle’ fracture to the sacrum posteriorly, which is felt as low-back/buttock pain when moving the legs. LC-1 fragility fractures result from a low energy fall from a standing height or less and most often affect women, with the likelihood of fracture increasing with age (1-3).

LC-1 fractures are often painful, with pain made worse by movement, which inevitably results in a period of reduced mobility. While this period may only last for a month or two, it is estimated that 25% of patients experience pain for up to five years afterwards(4). Patients with LC-1 fractures usually fall into two main groups: those that can mobilise, albeit with some degree of pain, and those where pain strongly affects a patient’s ability to ‘get going’. Patients that fail to mobilise due to ongoing pain are at greater risk of immobility-related complications(5). These complications include respiratory tract infections, urinary tract infections, pressure sores, and venous thromboembolic events (VTE) such as deep vein thrombosis or pulmonary embolism(5, 6). These individuals are also at risk of systemic sarcopenia (irreversible muscle wasting), disabling loss of confidence and permanently decreased levels of independence, often leading to increased care requirements. Inability to return to independent living can result in utilisation of intermediate care or residential facilities(7, 8). Such is the loss of confidence and muscle strength/conditioning in certain patients following LC-1 fracture, they do not regain their pre-injury level of ambulation or their prior independence with activities of daily living(1, 3, 9, 10). Additionally, individuals with LC-1 fractures have reported emotional stress, family strain, employment and financial difficulty, sleep disturbance, and anxiety(11). Pelvic fractures are also associated with increased mortality, with a total in-patient mortality rate of 9%, and an all-cause mortality rate within three months of fracture of 13%(12). All-cause mortality following pelvic fracture is around 50% at three years(2). Progress in the treatment of LC-1 fractures is needed to improve outcomes and quality of life (QOL).

With an ageing population, the incidence of pelvic fractures is rising. The UK age-specific incidence of pelvic fractures (based on a single centre) has increased from 39.6/100,000 (95% CI: 31.8 to 48.1) in 1997 to 71.6/100,000 (58.4 to 81.0) in 2007-2008 amongst people 65 years and older; 84% of these had pubic rami fractures(13). This increase is supported by evidence from other countries e.g. in Finland (based on national data) where the incidence, amongst people 60-years and older, has increased from 20/100,000 in 1970 to 92/100,000 in 1997(14). The estimated median treatment cost of pelvic ring fractures in Europe (acute hospital, surgery, rehabilitation, physiotherapy, and work-related absence) is €33,710 per patient (interquartile range €23,266 to €51,012), which is more costly than hip fractures(15).

## The current standard care for LC-1 fragility fractures

The current standard treatment for LC-1 fragility fractures in the UK is non-surgical management and to ‘mobilise as pain allows’(5, 16, 17). For many patients this is successful, and they are able to get up within a few days of injury and mobilise with an assistive device. However, pain can lead to immobility, leaving this predominantly older adult population at risk of significant complications.

Unlike LC-1 fragility fractures, fractures involving the upper end of the femur in older adults (also known as ‘hip fractures’), are invariably treated surgically, with either internal fixation of the bone or joint replacement being mandated within 36-hours of injury(18, 19). This is because patients with conservatively managed hip fractures are known to heal significantly worse than those that undergo surgery, the long-term risks to the patient resulting from prolonged immobility due to pain are much more severe than the immediate risks of surgery. Despite LC-1 fractures being similarly disabling for some patients in terms of pain and immobility and occurring in the same patient group as hip fractures, to date, it has not been shown whether or not older adult patients with LC-1 fractures would heal significantly better with surgery than conservative management. Traditional pelvic implants carry poor ‘bite’ or ‘purchase’ in low-quality osteoporotic bone around the pelvis and surgeons have been reluctant to offer surgery to patients with LC-1 fractures. The current standard of care for LC-1 fractures is for patients to be prescribed pain relief medication and mobilise with physiotherapist input as best they can until the fracture eventually heals.

Until recently, there has not been an effective operation to treat osteoporotic LC-1 fractures. External fixators, consisting of pins inside the pelvis connected to bars and clamps outside of the skin, are cumbersome, poorly tolerated and carry a high incidence of pin-site infections and soft tissue problems(20). An alternative is surgical fixation of the back of the pelvis with ilio-sacral screws(3). Although these are effective for certain fracture configurations, in the majority of older patients these screws carry poor ‘purchase’ in osteoporotic bone, leading to ineffective fracture stabilisation and persistence of pain(5).

## Surgical fixation with INFIX device

The INFIX is an anterior pelvic fixation device that resembles a traditional external fixator, in that it has screws that are secured into the pelvic bone, and these are connected by a metal bar across the front of the patient. Unlike traditional external fixation devices, INFIX is fitted internally, sitting entirely underneath the patient’s skin, with no external metalwork visible. This has two potential benefits over external fixation: it is less cumbersome and inconvenient to patients, compared with pins, clamps and bars protruding out of the skin. It also does not have pin-sites (where the bone-pins exit through the skin), which make traditional external fixation very susceptible to local infection. The INFIX technique involves percutaneous placement of screws in the pelvic bone and connects them with a bar under the skin(21). The pelvic bone where the screws are placed is generally strong and easy to visualise intra-operatively, even in very osteoporotic bone, making internal fixation (e.g. INFIX) a much more appealing surgical option for these fractures. Although a proportion of implants need to be removed; this is usually done as a day case procedure. INFIX is widely used in younger patients with high energy fractures. It is now a well described technique with a number of peer-reviewed series confirming its safety(22). It is therefore a widely-practiced, rather than ‘novel’ technique and is technically straightforward to carry out.

**Justification for the trial**

A systematic review found no robust evaluations, particularly randomised controlled trials (RCTs), of the effectiveness of internal fixation with INFIX in patients with osteoporotic LC-1 fractures(23). The review identified five case series, with four being retrospective. Participants were 64 or over and most had sustained their injury from a low energy fall. A variety of fixation techniques were used. Of the 225 patients in the five studies, most had internal devices, with 25 having external fixation; most patients had more than one type of fixation.

In the single series evaluating INFIX alone, 19 of the 29 patients had LC-1 fractures(24). Six patients had anterior fixation with INFIX alone and the remaining 23 had INFIX with additional internal fixation. Post operatively 22 of the 29 (76%) returned to their premorbid walking status, and a further six patients had some deterioration but remained ambulatory. Chronic pain (n=3, 10.3%) and painful lateral femoral cutaneous nerve hyperaesthesia (n=8, 27.5%) were prevalent after INFIX fixation. Other complications reported included: failure to return to premorbid walking status, infections, implant loosening, pneumonia, and thrombosis.

Our search of ClinicalTrials.gov for ongoing studies identified a trial in the United States of surgical versus non-surgical management of patients aged between 18 and 80 with lateral compression type 1, 2 and 3 pelvic fractures in 130 participants. The aim of this trial is to determine which patients would benefit from early surgical stabilization(25). We are also aware that NIHR Research for Patient Benefit (RfPB) have funded TULIP, a feasibility trial of surgical versus non-surgical treatment of LC-1 fractures of the pelvis in non-fragility fracture patients. This study is complementary to TULIP as it investigates their excluded population (i.e., fragility fracture patients).

The pelvic fracture community is at a key point in considering adopting internal fixation devices such as INFIX in the management of LC-1 fractures. In August 2016, we conducted a survey of 32 pelvic surgeons across the UK, of whom 29 responded; 70% felt there was a potential role for treating older patients with low-energy LC-1 fractures with INFIX if they fail to mobilise effectively due to pain.

We now have a device which has the potential ability to effectively stabilise LC-1 fractures in older adults, thereby potentially allowing them to mobilise sooner and prevent long-term complications of immobility. The intervention is increasingly used by pelvic surgeons in Major Trauma Centres (MTCs) for people with high energy fractures. However, more evidence of effectiveness is needed to evaluate the use of the INFIX device in older patients with fragility fractures. We will investigate the effectiveness, safety, and cost-effectiveness of internal fixation with devices such as INFIX compared to non-surgical treatment in older adults.

We are aware that this trial may be challenging to recruit to as the intervention involves an additional surgery not performed in standard care, furthermore, the target population (older adults) is a patient group that may have reservations about having surgery. A patient and public involvement (PPI) group has had input into the recruitment and consent process and helped to make our patient information sheets accessible. To test the feasibility of recruiting to this study an internal pilot phase will be included.

**Objectives**

The objectives of this trial are to:

1. Undertake a 12-month internal pilot to obtain robust estimates of recruitment and confirm trial feasibility.
2. Undertake a parallel group multi-centre RCT to assess the effectiveness of surgical fixation with INFIX versus non-surgical management of LC-1 fragility fractures in older adults. The primary outcome is average patient quality of life and function, over 6 months, assessed by the patient-reported EuroQol 5 Dimension, 5-Level scale (EQ-5D-5L) measured at baseline, 2 weeks, 6 weeks, 12 weeks, and 6 months.
3. Undertake an economic evaluation to compare the cost-effectiveness of surgical fixation compared to non-surgical management, to determine the most efficient provision of future care and to describe the resource impact on the NHS for the two treatment options.
4. Undertake a long-term review of patient wellbeing (EQ-5D-5L and mortality) 12 months after entering the trial.

**Methods**

**Trial design**

This study is a multi-centre, randomised controlled, parallel group superiority trial, with a 12-month internal pilot phase to assess assumptions about recruitment and provide guidance on optimising the trial processes before proceeding to the main trial phase. The allocation ratio of non-surgical management to INFIX surgery is 1:1.

**Study setting**

The study will be undertaken at up to 21 NHS MTCs across England, Scotland, Wales and Northern Ireland, planned sites are shown in Table 1. All sites will have surgeons who are experienced in doing these operations or who have the capacity to be trained.

**Table 1: Participating NHS Trusts**

|  |
| --- |
| **NHS Trust** |
| Bart’s Health NHS Trust |
| North Bristol NHS Trust |
| Cambridge University Hospital NHS Foundation Trust |
| Kings College Hospital NHS Foundation Trust |
| Brighton and Sussex University Hospitals NHS Trust |
| Oxford University Hospitals NHS Foundation Trust |
| South Tees Hospitals NHS Foundation Trust |
| Cardiff and Vale University LHB |
| University Hospitals Coventry and Warwickshire NHS Trust |
| St Georges University Hospitals NHS Foundation Trust |
| Imperial College Healthcare NHS Trust |
| Liverpool University Hospitals NHS Foundation Trust |
| Northern Care Alliance NHS Foundation Trust |
| NHS Grampian, Aberdeen Royal Infirmary |
| University Hospitals Plymouth NHS Trust |
| NHS Lothian |
| Sheffield Teaching Hospitals NHS Foundation Trust |
| Hull and East Yorkshire Hospitals NHS Trust |
| Leeds Teaching Hospitals NHS Trust |
| University Hospital Southampton NHS Foundation Trust |
| NHS Greater Glasgow and Clyde |
| Nottingham University Hospitals NHS Trust |
| University Hospital Birmingham NHS Foundation Trust |
| University Hospitals of North Midlands NHS Trust |
| Portsmouth Hospitals NHS Trust |

**Eligibility criteria**

Patients who meet all the inclusion criteria and none of the exclusion criteria will be eligible for the trial. Eligibility will be assessed by research nurses/associates and must be confirmed by a surgeon or clinician authorised in the trial delegation log prior to recruitment.

**Inclusion criteria:**

* Patients aged 60 years or older.
* An LC-1 pelvic fracture, arising from a low energy fall from standing height or less.
* Patient unable to mobilise independently to a distance of around 3 meters and back due to pelvic pain (or perceived pelvic pain) 72 hours after injury. Use of a walking aid and verbal guidance are permitted, however physical assistance is not.

**Exclusion criteria:**

* Unable to perform surgery within 10 days of injury.
* Surgery is contra-indicated due to soft tissue concerns, or because patient is not fit for anaesthetic (spinal or general).
* Patients who were non-ambulatory or required physical assistance to walk, prior to their injury (use of a walking aid is permitted).
* Concomitant injury or poly-trauma that impedes mobilization.
* Fracture configurations not amenable to internal fixation using INFIX, with or without ilio-sacral screws.
* Patients who test positive for COVID-19 within 72 hours of admission (applicable only where testing is standard of care).

Participating surgeons must be familiar with the surgical procedure (have previously conducted 10 or more INFIX procedures or undergo training until the CI confirms that they are sufficiently experienced). Level of experience will be recorded, and no grade of surgeon will be excluded from performing the procedure. In addition, all surgeons will be required to watch a training video and read a summary guidance document.

There will be no specific requirements in place on who can deliver the non-surgical rehabilitation which will be delivered in line with routine practice at the participating site.

Key trial outcomes are patient reported and not validated in languages other than English. Patients who do not have adequate verbal or written English skills or do not have family or friends who can sufficiently support them in the completion of the questionnaires will not be recruited.

**Informed consent**

Once eligibility is confirmed, hospital research staff will obtain written informed consent from patients who have capacity. This study will also include patients who lack capacity, and in this instance, consultee agreement or consent will be obtained in line with national guidelines.

Routine capacity assessments performed by clinical staff, on admission will be used in conjunction with research staff judgement to determine whether the patient has capacity to provide consent.

Consent or consultee agreement will be sought for follow-up beyond the duration of the trial to allow the possibility of future long-term follow-up including the use of routinely collected Hospital Episode Statistics (HES) and Office of National Statistics (ONS) data.

**Interventions**

**Non-surgical management**: This is the standard care for LC-1 fragility fractures in this patient population in the UK. Patients are routinely administered pain relief and seen by a physiotherapy team who mobilise patients as pain allows.

**INFIX surgery:** INFIX is a type of anterior internal fixation device; it is fitted internally underneath the patient’s skin. The technique involves percutaneous placement of long pedicle screws within the pelvic bone, these are connected by a metal rod across the front of the patient under the skin. As this is a pragmatic study, surgeons can use their preferred INFIX device. The primary fixation for every patient is INFIX. If the surgeon feels that the fracture configuration in a patient warrants supplementary ilio-sacral screw fixation, this is permissible under the trial, provided adequate intra-operative pelvic imaging can be achieved. Within this study, INFIX surgery is required to be performed within 10 days of injury.

All participants will receive pain relief and physiotherapy as per standard care at the participating site, they will also be provided with a trial rehabilitation leaflet. This leaflet details suggested exercises to perform and is intended to supplement and not replace advice given by the site physiotherapy team. Instructions will state ‘immediate weight bearing, as pain allows’. For both groups, the goals of physiotherapy are to improve function, strength and range of movement in both legs, while aiming to get patients back to independent mobility as soon as possible.

If a patient randomised to the surgical arm tests positive for COVID-19 prior to their surgery, they will cross over to the non-surgical arm. If a patient randomised to INFIX surgery later requests not to have surgery, then non-operative management should be given. INFIX surgery is not routinely offered as standard care, therefore if a patient randomised to non-surgical management requests INFIX surgery the site may be unable to offer this.

In either the non-operative management or the INFIX surgery group, if any patient’s course is complicated by excessive pain when mobilising, a repeat radiograph is clinically indicated, followed with a review by a pelvic surgeon, as would be the normal standard of care. No concomitant care is prohibited, data will be collected on all clinic visits and medication required during the trial. This includes monitoring the number and duration of physiotherapy sessions as well as the pain relief medication that patients in both groups receive as part of their rehabilitation.

There are no special compensation arrangements for this study, the normal National Health Service complaints procedure is available to anyone who has concerns. This study will be sponsored by Bart’s Health NHS Trust. NHS indemnity scheme will apply.

**Outcomes**

**Primary Outcome: Health related quality of life: EQ-5D-5L**

The primary outcome measure is average patient quality of life, over 6 months, assessed by the patient-reported outcome measure, EQ-5D-5L. EQ-5D-5L will be collected at baseline (for today and one week prior to injury (adapted with permission)), 2 week, 6 week, 12 week, and 6 month time points, as well as an optional 12 month follow up point for those recruited early to the study and who reach this time point within the planned follow-up period.

The EQ-5D-5L is a validated generic patient-reported outcome measure ([www.euroqol.org](http://www.euroqol.org)), including validation in patients with hip fractures and orthopaedic patients with cognitive impairment(26). The descriptive system has five health domains (mobility; self-care; usual activities; pain/discomfort and anxiety/depression) with five response options for each domain (no problems, slight problems, moderate problems, severe problems, and extreme problems). In addition, it has a health status visual analogue scale (VAS) which measures self-rated health with endpoints ranging from ‘the best health you can imagine’ to ‘the worst health you can imagine’. The EQ-5D-5L will be scored according to the User Guide(27). The measure is easily completed and can be completed by proxy (which is important for our clinical population), and it can also be scored for those who die during follow-up. EQ-5D-5L data will be collected in either patient questionnaires or in proxy questionnaires for those who lack capacity. Details of how scores will be aggregated and analysed are given in the statistical methods section. The EQ-5D-5L will be also used to estimate quality-adjusted life years (QALYs) for the cost-effectiveness analysis.

**Secondary Outcomes**

**Physical function:**

Physical function will be measured using the Patient Reported Outcome Measures Information System (PROMIS) Lower Extremity Function and the Timed Up and Go test (TUG).

PROMIS Lower Extremity Function data will be collected in the patient questionnaires (or proxy questionnaires for those who lack capacity) at baseline, 2 week, 6 week, 12 week and 6-month time points. PROMIS is a set of validated person-centred measures that evaluates physical, mental, and social health in adults and children(28). The full item bank can be used for computer adaptive testing but is also available in a range of subscales and short forms to measure different aspects of health. Lower Extremity Function (Neuro-QOL Short Form v1.0 – Lower Extremity Function (Mobility)) is an extremely important outcome domain for people with an LC-1 fracture, due to the impact of the injury on ability to mobilise. This brief measure (Lower Extremity Function), administered as a paper-based questionnaire, is designed to reduce respondent burden and has been deemed to have good face validity with our PPI group.

The TUG will be undertaken at 12 week follow up point only when the visit is conducted in the clinic setting (there will be no attempt to perform this where a remote visit is undertaken). This test assesses walking speed, mobility, balance, and fall risk. It is an established test used routinely in practice and has been validated for reliability(29, 30). An LC-1 fracture can impact significantly on ability to mobilise and this clinic-based measure will complement the patient reported outcome measure PROMIS Physical function.

**Global Mental Health:**

Global mental health will be measured using the PROMIS Scale v1.2 – Global Health Mental 2a.

This is a two-question subscale on global mental health, it will be collected in the patient and proxy questionnaires at baseline, 2 week, 6 week, 12 week and 6-month time points. Inclusion of this subscale was highly commended by our PPI group.

**Pain:**

Pain will be measured using a Visual Analogue Scale (VAS), this is a unidimensional measure of pain intensity in adults(31). We will use a scale ranging from ‘no pain’ to the ‘worst imaginable pain’ to measure average pain over the last week. This data will be collected from participants with capacity only, at baseline, 2 week, 6 week, 12 week, and 6 month time points as well as an optional 12 month follow up point for those recruited early within the study.

**Delirium:**

Delirium will be measured by the Abbreviated Mental Test Score (AMTS) and the 4AT Rapid Assessment Test for Delirium. These tests will be conducted at baseline, 2 weeks and at 12 weeks. The 12-week tests will indicate whether new onset delirium is temporary or a permanent change.

AMTS is a short, verbal test widely used in clinical practice to screen for confusion and dementia(32, 33). It is used across many areas of medicine and despite being developed in 1972(33), recent data confirms its validity in emergency admissions in older adults within UK hospitals(32).

*4AT Rapid Assessment Test for Delirium* is a short, practical instrument validated for detecting delirium, routinely used in clinical practice(34, 35). The strengths of the 4AT Rapid Assessment Test for Delirium is that it can be used on patients that are drowsy or agitated (which is common after surgery), it does not require specialist training, and takes less than 2 minutes to complete.

Post-operative delirium is a known complication for older individuals, particularly those with dementia. The incidence in a hip fracture surgery population has been calculated as 24%(36). Therefore, its use as an outcome measure will be to monitor this potential adverse effect of surgery. Post-operative delirium is associated with higher costs, functional decline, increased length of stay, discharge to a nursing home or care home, and higher mortality(37). Therefore, understanding which participants exhibit post-operative delirium will aid in the interpretation of the findings and outcomes post intervention.

**Imaging Assessments:**

A radiologic assessment of the pelvis will be performed between 12 weeks and 6 months to assess non-union or late displacement of the LC-1 fracture.

The rate of non-union or late displacement of LC-1 fractures that were treated initially non-operatively but which subsequently required internal fixation, has been reported as 4%(3), although this figure is not well corroborated by other studies. Such patients typically have ongoing symptoms from their pelvis and signs of displacement or non-union would be evident on follow-up x-rays from 12 weeks onwards. It is therefore critical in this study to have X-rays of both surgically treated and non-operative control groups for comparison, regarding non-union or displacement of the pelvic ring.

**Resource Use:**

Information on resource use throughout patients’ hospital stays and at discharge will be collected to assess the impact on the NHS as part of the economic evaluation. Data collected in clinic case report forms (CRFs) will include, length of hospital stay, medication, surgery details and details of therapy during rehabilitation. The 2 week and late discharge CRFs will also collect details on any aids or adaptations required and any change of place of residence (e.g. own home to residential care home) relative to baseline. Resource use data will also be collected in the 12-week patient questionnaire, from patients with capacity only. This will include information on any re-admittance to hospital, outpatient care received, any additional medications, aids or adaptions since discharge and return to work.

**Complications and Adverse Events:**

Information on expected complications, including additional surgery will be collected in the hospital CRFs at 2 weeks, at 12 weeks and at discharge (if after 2 weeks). Expected complications that will be recorded will include (but not be limited to) the following: neurological complications, deep wound infection (using Centres for Disease Control (CDC) and Prevention definition)(38), superficial infection (using CDC definition), rehospitalisation, re-operation (including removal of implant) and skin problems.

Lateral Cutaneous Nerve Injury is an Adverse Event of Special Interest (AESI), and information on this will be collected on an Adverse Event (AE) form. Patients will also be asked about this in the 2 week, 6 week, 12 week and 6 month questionnaires, as well as in the 12 month questionnaires for those who agree to this additional follow-up.

Information on any unexpected Adverse Events or any expected or unexpected Adverse Events that become Serious Adverse Events (SAEs) will be reported on the appropriate AE or SAE report form as discussed below.

**Mortality:**

Mortality rates of 10-15% have been reported in this population 6 months after the fracture. Therefore, checks will be made on patients’ status before mailing out follow up questionnaires at 6 and 12 months. Mortality will be reported as an outcome at 6 months, (and 12 months for those patients that agree to this additional follow-up).

**Table 2: Participant timeline**

|  |  |  |
| --- | --- | --- |
|  |  | Study Period |
|  |  | Post Allocation |
| **Time point** | **Enrolment / Baseline** | **Randomisation** | **2 Week** | **6 Week** | **12 Weeka** | **6 Month** | **12 Monthb** |
| Eligibility screen | X |  |  |  |  |  |  |
| Informed consent | X |  |  |  |  |  |  |
| Demographic datac | X |  |  |  |  |  |  |
| Randomisation |  | X |  |  |  |  |  |
| Surgical Fixation |  | X |  |  |  |  |  |
| Non-surgical management |  | X |  |  |  |  |  |
| EQ-5D-5L | Xd |  | X | X | X | X | X |
| PROMIS (LEF and GMH) | X |  | X | X | X | X |  |
| TUG |  |  |  |  | X |  |  |
| Pain VAS | Xe |  | X | X | X | X | X |
| AMTS | X |  | X |  | X |  |  |
| 4AT | X |  | X |  | X |  |  |
| Mortality |  |  |  |  |  | X | X |
| Resource Use Data |  |  | Xf |  | X | Xg | Xg |
| Imaging |  |  |  |  | X |  |  |
| Complications |  |  | X |  | X |  |  |
| COVID-19 statush | X |  | X | X | X | X | X |
| Adverse event reporting | X |  |  |  |  | X | X |
| Change in status form | X |  |  |  |  |  | X |

a Visit may be conducted remotely in the event of local restrictions arising from COVID-19. TUG assessment will not be completed where the visit is remote. Radiology assessment may be performed up to the 6 month time point. b Optional follow-up time point for those patients that reach this time point within the planned follow-up period. c Patient demographic data collected will include date of birth, gender, ethnicity, lifestyle, medical history and current medications, details of the fracture and any concomitant injuries and Rockwood frailty score in the week prior to injury. dData retrospectively collected for a week before the injury as well as on the day of baseline assessment. eThis question will ask about their pain, since their injury only. fIf the patient has not been discharged by the 2 week timepoint, health resource data will be collected via review of medical records following the point of discharge. gCollected for patients with capacity only. hCOVID-19 status will be recorded where routine testing has been undertaken on admission and patients will be asked to self-report results of any additional testing undertaken during follow–up.

**Sample size**

It is estimated that 600 participants are required to address the study objectives. The primary outcome is the EQ-5D-5L over 6 months. To be conservative, we took the lowest published estimate of the Minimal Clinically Important Differences (MCID) (0.074)(39) with an estimated standard deviation of 0.25 (estimated from the 0.30 reported by Adachi et al. for the 3L version(40) and adjusted down to account for the 5L version’s greater sensitivity). Based on these assumptions we would need to analyse 480 participants (240 per group) and, after accounting for loss to follow-up of 20%, we would need to recruit and randomise 600 participants for a study with 90% power (2p = 0.05).

**Recruitment**

The study will include an internal 12-month pilot phase to assess the assumptions about site set up and recruitment.

We will prioritise the setup of MTCs during the recruitment phase of the trial, training will be provided at Site Initiation Visits and training videos will be made available. Trial Coordinators will provide ongoing guidance and support to the local Principal Investigators (PI), treating clinicians and research staff at each centre to optimise screening and recruitment for their local circumstances. Clinical guidance will be sought from the CI as appropriate; email bulletins and email newsletters will be circulated to update staff on trial progress and any relevant reminders.

Potentially eligible patients will be recruited from inpatient wards (surgical, elderly care and medical). To identify eligible patients, the research associate will screen all patients 60 years old and over, admitted with an LC-1 fracture. Patient eligibility must be confirmed by a delegated surgeon or clinician. Eligible patients will be approached to discuss the study and given the Patient Information Sheet, they will have time to discuss the study with their family and/or friends, and they will have the opportunity to ask questions of the surgeon and the local research team.

The research team will share ideas of best practice from other sites, and we will seek advice from PPI members to develop strategies to maximise patient recruitment.

Internal Pilot

An internal 12-month pilot will address the question of whether there are a sufficient number of eligible patients identified and recruited in 12 months to make the trial viable within the proposed 36-month recruitment period.

The progression criteria agreed with the funder to be assessed at the end of the pilot will be to have a minimum of 19 sites open to recruitment, to achieve a recruitment rate of 1 patient/per month/per site (total of 148 patients randomised).

An average recruitment rate of one patient per centre per month would support a decision to progress to the main trial. An average rate of 0.80 to 0.99 per centre per month would suggest that a decision to progress may be supportable depending on other supplementary information available (e.g., number and characteristics of potential participants not approached, proportion not meeting eligibility criteria and reasons, proportion declining participation and reasons why) and whether any of the factors impeding recruitment could be remedied.

**Allocation of interventions**

The online L1FE Data Management System is an independent secure randomisation service for sequence allocation hosted by York Trials Unit (YTU) and accessed by research staff either by telephone or via the internet. Research staff who have been delegated the responsibility to randomise patients on their site delegation log will be granted access using a personal log in.

Once an eligible patient has consented and their baseline forms have been completed, research staff will record their information on the L1FE Data Management System. The system will confirm eligibility and then perform independent and concealed random allocation (1:1), using computer generated random permuted blocks of random sizes, stratified by centre. The patient will be allocated to either surgical fixation or non-surgical management.

Patients and treating clinicians will be informed of the allocation. As with many surgical trials, where the surgical site is clearly visible, it is not feasible to blind patients, surgeons, or outcome assessors. The primary outcome is a patient-reported measure, mitigating surgeon influence. All staff involved in analysing questionnaire responses will be blind to patients’ treatment allocation.

**Data collection and management**

Paper CRFs will be used to collect and record all outcome data. Data will be collected at recruiting sites by research staff on hospital CRFs and participants will complete CRFs by post. All CRFs will be returned to YTU for scanning and processing. All reporting of data collection will be undertaken in line with the Consolidated Standards of Reporting Trials (CONSORT) statement(41).

To minimise attrition, we will use multiple methods to keep in contact with participants. We will ask participants for full contact details (including mobile phone number and email address). We will also collect alternative contact details of someone who can be contacted if the participant changes address. Participants can complete the 2 and 12 week questionnaires in clinic when attending in person or they can be completed over the phone. The 6 week, 6 month and 12 month questionnaires will be either completed by post or over the phone for the patient’s convenience. Pre-notification letters will be sent out before the postal follow-up questionnaires are due, to help prime participants and a text message reminder will also be sent on the day participants are expected to receive the postal questionnaire. This has been shown to significantly reduce time to questionnaire response(42). There will also be 2 follow-up postal reminders and a telephone reminder at each time point if required. The telephone reminder will give participants the option to complete an abridged questionnaire (a minimum of the EQ-5D-5L). The study team will also call the participant when there is missing data on the primary outcome (and other missing data as feasible) when a postal questionnaire is returned. We will also write newsletters during the trial to keep the participants informed and engaged with the trial which can enhance response rates(43).

Participants are free to fully withdraw from the study at any point, however it is also possible for them to withdraw from only one aspect of the trial if participation becomes a burden. For example, participants can continue with either clinical visits only, postal questionnaires only or data collection from their hospital records only with no participant involvement. It is anticipated that these options will reduce the need for patients to fully withdraw from the trial and enable some useful data to still be collected.

Improving retention of participants is important to all RCTs and there is a need to develop and test interventions to improve retention. The L1FE trial will act as a host trial for an embedded trial, referred to as a Study Within A Trial (SWAT). The objective of this SWAT is to evaluate the impact of making a courtesy introductory telephone call to newly recruited trial participants on response rates to follow-up questionnaires compared with a written card with equivalent information, or nothing. This SWAT is registered on the MRC SWAT Repository. SWAT Ref 114: Effects of telephone calls or postcards to trial participants following enrolment on retention in a randomised trial.

**Data management**

An electronic management system will be used to track participant recruitment and study status as well as CRF returns. Data from CRFs will be processed by administrative personnel at YTU. Data will be verified through cross checking of the data against the hard copy of the CRF. The trial coordinator and statistician will write a Validation Plan for the CRFs in consultation with the YTU Data Manager. The Plan will include detailed coding for the CRFs and data query resolution rules/procedures. Quality Control will be applied at each stage of data handling to ensure that all data are reliable and have been processed correctly.

All paper records will be kept in locked locations for the duration of the study.

**Confidentiality**

Data will be handled in accordance with the Data Protection Act 2018, General Data Protection Regulation (GDPR) legislation, the latest Directive on Good Clinical Practice, and local policy.

All personal information collected about enrolled participants will be held electronically in a secure environment at the University of York, with permissions for access in line with Standard Operating Procedures (SOPs). All paper records containing personal information such as consent forms and consultee declaration forms will be stored safely in a separate compartment of a locked cabinet.

Clinical information will only be looked at by responsible individuals from the study team, the Sponsor, the NHS Trust, or from regulatory authorities; where it is relevant to the patient taking part in this research as he/she would have agreed to at the time of consent or consultee declaration.

The researchers and clinical care teams must assure that patients’ anonymity will be maintained and that their identities are protected from unauthorised parties. Once randomised, patients will be assigned a participant ID number. This will be used on all CRFs and individual participants will only be referred to by their participant ID number to maintain patient confidentiality. All study data will be completely anonymised for any analyses, reports or publications.

**Statistical methods**

**Statistical methods for primary and secondary outcomes**

Full analyses will be detailed in a statistical analysis plan (SAP), which will be finalised prior to the end of data collection, and which will be reviewed and approved by the independent data monitoring committee. Any exploratory analyses of sub-groups that are of clinical interest will be pre-specified in the SAP. This trial will be reported according to the CONSORT guidelines for clinical trials.

Statistical analyses will be on intention to treat basis with patients being analysed in the groups to which they were randomised. Analyses will be conducted using 2-sided significance tests at the 5 % significance level (unless otherwise stated in the SAP).

A CONSORT flow diagram will be provided to display the flow of participants through the study. The number of participants withdrawing from the trial will be summarised with reasons where available. Baseline characteristics will be presented by trial arm. All trial outcomes will be reported descriptively by trial arm at all time points at which they were collected. Continuous baseline and outcome data will be summarised as means, standard deviations, medians and ranges, whereas categorical data will be summarised as frequencies and percentages.

The primary analysis will be a mixed effects linear regression model, with EQ-5D-5L scores at 2 week, 6 week and 12 week and 6 month time points as the dependent variable, adjusting for baseline EQ-5D-5L, randomised group and other pertinent baseline characteristics as fixed effects. Potential clustering at hospital site level will be controlled for by including it in the model as a random effect. The model will account for the correlation of scores within patients over time by means of an appropriate covariance structure. The estimated treatment group differences across all time points will be reported as the primary endpoint with 95% confidence interval and associated p-value. Secondary analyses will include an estimate of treatment group differences at each time point from the same model.

The secondary outcomes; PROMIS: Lower Extremity Function score, TUG score, AMTS score, 4AT score, PROMIS Scale v1.2: Global Health Mental 2a score and Pain VAS will be analysed by similar mixed effects linear regression models. Mortality will be analysed using a logistic regression model.

An economic evaluation analysis will be conducted from the recommended NHS and personal social services (PSS) perspective according to National Institute for Health and Clinical Excellence (NICE) guidance(18). Data will be collected on the costs and outcomes of each trial participant during the period between randomisation and 6 months post-randomisation as well as an optional 12-month time point. The internal pilot phase will permit testing of the data collection forms to be used in the economic analyses in terms of validity, consistency, reliability, and response rate (e.g., missing data). Trial participants will be asked to complete economic resource use questionnaires at 12 weeks and 6 months as well as at the optional 12-month time point. These will report hospital (e.g., inpatient, outpatient, A&E), community, and social care resources used; and for the purposes of secondary analysis, costs associated with lost productivity and out-of-pocket costs. Hospital forms will be specifically designed to collect information on the cost of surgery (e.g., time in theatre, staff time, consumables and devices, nights in hospital after the procedure), complications, physiotherapy, and removal of devices. Relevant UK unit costs, such as NHS Reference costs and PSS Research Unit costs of health and social care, will be applied to each resource item to value total resource use in each group.

Health outcomes will be expressed in terms of the Quality Adjusted Life Years (QALYs) using the EQ-5D-5L data collected at baseline, 2 weeks, 6 weeks, 12 weeks and 6 months post-randomisation The EQ-5D-5L health states will be valued following the NICE position statement(44). QALYs will be calculated using the area under the curve analysis(45).

Costs and QALYs will be synthesised to generate an incremental cost-effectiveness ratio (ICER). Regression methods will be used to allow for differences in prognosis variables. The pattern of missing data will be analysed and handled by means of multiple imputation (MI) methods if deemed appropriate according to the missing data pattern in the L1FE dataset(46). A range of sensitivity analyses will be conducted to test the robustness of the results using different scenarios. The uncertainty will be presented using cost-effectiveness acceptability curves. The probability that each intervention is cost-effective will be reported at the cost-effectiveness thresholds of £20,000 to £30,000/QALY and £13,000/QALY as suggested by recent research(47, 48), if results deem appropriate (i.e., there is a non-dominant situation in the trial-based evaluation). We will undertake a secondary analysis to extrapolate the results of the trial beyond the study follow-up.

A detailed economic analysis plan will be agreed with the TSC before all data has been collected.

**Interim analyses**

There is an internal 12 month pilot phase to assess the feasibility and recruitment rate of this study.

Detailed screening logs will be kept by participating centres and the recruitment rate will be reported by month, by hospital site and overall from the data collected. A CONSORT diagram will be constructed to show the flow of participants through the study and the following outcomes calculated: number of eligible patients; proportion of eligible patients approached for consent; proportion of eligible patients not approached and reasons why; proportion of patients approached who provide consent; proportion of patients approached who do not provide consent and reasons why; proportion of patients providing consent who are randomised; proportion of patients randomised who do not receive the randomly allocated treatment and reasons why; and proportion of patients dropping out between randomisation and follow-up and reasons why. For each of the above we will collect data on whether consent was sought from a patient, or for patients who lack capacity whether a personal or nominated consultee was asked to give declaration.

Details of all participating surgeons’ prior experience with the INFIX procedure will be collected as part of the trial. Equipoise is an essential concept in trials and will be covered during the training delivered as part of the site set up process. The assumption of surgeon equipoise will be monitored during recruitment by scanning reasons for exclusion during screening and reasons for crossover following randomisation that may reflect surgeon preferences.

These data will be compared against the study’s recruitment assumptions and progression targets to inform continuation of the trial or relevant modifications to improve recruitment rates. The final decision on progression from the pilot phase to main trial will be made by the funding body.

**Methods for additional analyses (e.g., subgroup analyses)**

A subgroup analysis will be performed to explore the potential effect of patients’ knowledge of which treatment they received (allocation cannot be blinded) and their experience of this treatment on the results of the trial. This will be for the primary outcome only and the interaction term between preference and treatment group will be included in the primary analysis model as described in the previous section.

For patients who are eligible and opt in to complete the 12-month follow-up questionnaire, the primary analysis model will be extended and the treatment effect with associated 95% CI reported for the 12-month follow-up time point.

**Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data**

The number of participants not receiving their allocated treatment will be reported by group. In the presence of non-adherence with randomised treatment, a CACE analysis will be undertaken using an instrumental variables regression model.

The primary analysis model will use a mixed effects regression model which implicitly assumes missing outcome data are missing at random (MAR). However, it is possible that participants who failed to complete their follow-ups differed from those who did complete. This would mean the data were missing not at random and would represent a departure from the MAR assumption. The sensitivity of the primary analysis results to departures from the MAR assumption will be explored using a pattern-mixture model, implemented using the rctmiss command.

**Plans to give access to the full protocol, participant level-data and statistical code**

The full protocol is available via the funder website:

ttps://www.fundingawards.nihr.ac.uk/award/16/167/57. Requests for other data or documentation should be made by contacting the corresponding author.

**Oversight and monitoring**

The primary responsibility for monitoring the safety of participants in clinical trials lies with the trial Sponsor. Data monitoring will be undertaken by the Trial Management Group (TMG), Trial Steering Committee (TSC) and a Data Monitoring and Ethics Committee (DMEC), on behalf of the Sponsor and Funder. The project will also be monitored by the Sponsor for whom a representative will be invited to attend the TMG and TSC meetings. Regular progress reports will be submitted to the Funding Body.

The TMG will oversee the day-to-day management of L1FE and is chaired by the CI. Other members include the trial statisticians, trial manager, trial coordinators, health economist, and other co-applicants. The role of the TMG is to monitor all aspects of the conduct and progress of the trial, ensure that the protocol is adhered to and take appropriate action to safeguard participants and the quality of the trial itself. The TMG will meet monthly by video or teleconference from the start of the study until the end of the pilot phase and quarterly for the remainder of the study.

The TSC is independent and has been established to provide overall supervision for L1FE on behalf of the Sponsor and Project Funder and to ensure that the project is conducted to the rigorous standards set out in the Department of Health’s Research Governance Framework for Health and Social Care and the Guidelines for Good Clinical Practice (GCP). This committee comprises of an Independent Chair who is a Professor of Clinical Trials, a consultant orthopaedic surgeon with expertise in the procedure, a public contributor, a Consultant Physiotherapist, a representative from the sponsor, the CI and the Trial Coordinator/Manager. Other study collaborators may also attend the meeting with the agreement of the Chair. The TSC will meet at least annually and will work to an agreed Charter.

The DMEC is chaired by a statistician, with other members comprising of experts in the clinical area: Professor of Trauma & Orthopaedics, Senior Lecturer in Physiotherapy, and the CI. The role of the DMEC is to review accumulating data in L1FE and advise the Sponsor (directly or indirectly) on the future management of the trial. The DMEC will review safety and efficacy data as well as quality and compliance data. The DMEC will review all serious adverse events which are thought to be treatment related and unexpected. The independent members of the DMEC will be allowed to see unblinded data. The DMEC will meet at least annually or more frequently if the committee requests, and will work to an agreed Charter.

Any substantial amendments will be submitted to the Health Research Authority (HRA) (and Research Ethics Committee (REC) where required) having been agreed with: the funding body, Sponsor, TSC, DMEC and the TMG. Minor modifications to the protocol will be agreed with the TMG and Sponsor before submission for approval to the HRA. All amendments will be implemented in the NHS organisations in agreement with the guidance and approval of the HRA. All amendments will be listed in the published final report to the funding body.

**Adverse event reporting and harms**

Due to the age of this patient population and likelihood of unrelated AEs occurring, any expected AEs will be considered complications and data will be collected on these in the CRFs as described above.

We will collect data for the AESI and any unexpected adverse events that are related to treatment for the original injury. We will collect AE data from the point of randomisation to 6 months post randomisation for all patients and up to 12 months post randomisation for patients that agree to this additional time point. All AEs will be listed on the appropriate AE CRF for routine return to YTU.

Expected and unexpected SAEs will be reported if they appear to be related to any aspect of taking part in the study and occur within 6 months of randomisation for all patients and up to 12 months post randomisation for patients that agree to this additional time-point. All SAEs will be entered onto the SAE reporting form and forwarded to YTU within 24 hours of the investigator becoming aware of them. Once received, causality and expectedness will be confirmed by the CI. SAEs that are deemed to be unexpected and related to the trial will be notified to the Research Ethics Committee (REC) and sponsor within 15 days. All such events will be reported to the TSC and DMEC at their next meetings. Follow up reports a month later may be requested by the CI for their review to ensure that adequate action has been taken and progress made. All participants experiencing SAEs will be followed-up as per protocol until the end of the trial.

The summary of complications, deaths, AEs, and SAEs experienced by the participants will be reported by treatment group.

**Frequency and plans for auditing trial conduct**

Central monitoring will be undertaken, with triggered on-site monitoring if significant issues are identified. Direct access will be granted to authorised representatives from the sponsor, host institution and the regulatory authorities to permit study-related monitoring, audits and inspections.

**Dissemination plans**

Through the planned outputs, the study is expected to play a key role in enhancing the evidence base on the effectiveness and cost-effectiveness of surgical fixation for the management of pelvic fractures. The economic component will help us to identify the most efficient provision of future care and thus savings to the NHS and society.

The executive summary and copy of the trial report will be sent to NICE and other relevant bodies, including Clinical Commissioning Groups, so that study findings can inform their deliberations and be translated into clinical practice nationally. We will work with the relevant Specialty Advisory Committees (SAC) to incorporate the findings into the training curriculum for clinicians who will undertake treatment for pelvic fractures. We will use several dissemination channels to ensure that patients and the public are also informed about the results of the study. We will produce the following outputs:

* A HTA research monograph will be produced.
* In conjunction with patient members of the team, we will generate patient information for “Shared Decision Making” based on findings from this trial.
* The results of the study will be presented at national and international surgical meetings such as the British Orthopaedic Association Annual Congress, the UK Orthopaedic Trauma Society meeting, the North American Orthopaedic Trauma Association the European Federation of National Associations of Orthopaedics and Traumatology (EFFORT), Société Internationale de Chirurgie Orthopédique et de Traumatologie (SICOT), and the American Academy of Orthopaedic Surgeons.
* The results will be shared with relevant charities such as the Royal Osteoporosis Society to ensure wider dissemination amongst the public. Results will also be presented at meetings led by the Chartered Society of Physiotherapy and the Royal College of Physicians to teach the wider multidisciplinary team.
* The findings will be published in peer reviewed high impact general medical and orthopaedic journals such as Lancet, the BMJ or similar.
* A summary of the study report, written in lay language will be produced and made available to participants, members of our user group and relevant patient-focused websites.
* We will seek to raise the profile of the trial via social media including a dedicated Twitter account. This will be aimed at participating site staff and focus on trial progress, trial related events, and publicising research outputs.
* If found to be effective, the MTC pelvic specialist surgeon co-applicants will explore ways of cascading training in the technique to orthopaedic surgeons in NHS hospital Trauma Units to ensure consistency of best practice across the NHS.

**Discussion**

This study aims to further the knowledge of treatment options for patients aged 60 years and older with LC-1 fragility fractures, a common and painful injury that can lead to long term immobility in some patients. The clinical and cost effectiveness of two treatments options will be compared, these are non-surgical management, the current standard of care and INFIX surgery, an internal fixation device which is frequently used to stabilise this fracture in younger patients. The study has an inbuilt 12 month pilot phase to test the feasibility of recruiting to this study. Results will be disseminated through peer reviewed publications and the evidence will help to inform clinical practice.

 **Trial status**

The current version of the protocol is L1FE Trial Protocol V3.2 22nd December 2020.

Recruitment to the L1FE trial started in August 2019 and recruitment was anticipated to be completed at the end of March 2022. However, recruitment to the L1FE study was suspended in March 2020 due to the COVID-19 pandemic. Amendments were made to the trial protocol in response to the pandemic, to increase the flexibility of follow-ups with the option for more data collection to be done remotely. Recruitment restarted on 15th March 2021 with a plan to continue the initial 12 month internal pilot phase for a further 6 months until 15th September 2021. On the 13th of August 2021, the decision was made that the study was not feasible, in part due to a change in patient pathways in response to the COVID-19 pandemic. All sites were notified to stop recruitment with immediate effect.

At the time of manuscript submission, enrolled patients remain in follow-up phase with last patient last visit anticipated in November 2021.

**Abbreviations**

|  |  |
| --- | --- |
| AE | Adverse event |
| AESI | Adverse Event of Special Interest |
| CEAC | Cost-Effectiveness Acceptability Curves |
| CI | Chief Investigator |
| CONSORT | Consolidated Standards of Reporting Trials |
| CRF | Case Report Form |
| DMEC | Data Monitoring and Ethics Committee  |
| EQ-5D-5L | EuroQol 5 Dimension, 5-Level scale |
| GCP | Good Clinical Practice |
| GDPR  | General Data Protection Regulation |
| HES | Hospital Episode Statistics |
| HRA | Health Research Authority |
| ICER | Incremental Cost Effectiveness Ratio |
| LC-1 | Lateral Compression Type 1 |
| MTCs | Major Trauma Centres |
| NHS | National Health Service |
| NICE | National Institute for Health and Clinical Excellence |
| NRS | Numerical Rating Scale |
| ONS | Office of National Statistics |
| PI | Principal Investigator |
| PPI | Patient and public involvement |
| PROMIS | Patient Reported Outcome Measures Information System  |
| PSS | Personal Social Services |
| QALY | Quality Adjusted Life Year |
| RCT | Randomised Controlled Trial |
| REC | Research Ethics Committee |
| SAE | Serious Adverse Event |
| SAP | Statistical Analysis Plan |
| SD | Standard Deviation |
| SDV | Source Data Verification |
| SOP | Standard Operating Procedure |
| SWAT | Study Within A Trial |
| TMF | Trial Master File |
| TULIP | **T**rial of s**u**rgical versus non-surgical treatment of **l**ateral compression **i**njuries of the **p**elvis with complete sacral fractures (LC-1) in the non-fragility fracture patient - a feasibility study  |
| TUG | Timed Up and Go Test  |
| VTE | Venous Thromboembolism |
| YTU | York Trials Unit |

**Declarations**

**Acknowledgements**

**L1FE Trial Sponsor:** Bart’s Health NHS Trust

**L1FE Trial Patient Representatives:** Thank you to all members of the Patient and Public Involvement group for giving their input and advice.

**Trial Steering Committee:** Professor Deborah Stocken (Chair - Independent member), Professor Alan Johnstone (Independent member), Dr Kika Konstantinou (Independent member), Mr Alan Ereira (Independent member), Dr Katherine Davies (Independent member).

**Data and Ethics Monitoring Committee:** Professor Graeme MacLennan (Chair – independent member), Professor Ian Pallister (independent member), Dr Cherry Kilbride (independent member).

The authors would like to thank all participants for their involvement in the study and all the principal investigators and their teams at each of the L1FE participating sites.

**Authors’ contributions**

P Bates: Conceptualized the study, developed the methodology, wrote, edited, and reviewed the manuscript.

E Cook: Trial Manager, contributed to methodology, wrote, edited, and reviewed the manuscript.

J Laycock: Trial coordination activities, contributed to methodology, wrote, edited, and reviewed the manuscript.

M Acharya: Developed the methodology, wrote, edited, and reviewed the manuscript.

M R Backhouse: Trial coordination activities, contributed to methodology, edited, and reviewed the manuscript.

B Corbacho: Developed the health economic aspects of methodology, wrote, edited, and reviewed the manuscript.

L Doherty: Trial Support Officer activities, edited and reviewed the manuscript.

D Forward: Conceptualized the study, developed the methodology, wrote, edited, and reviewed the manuscript.

C Hewitt: Conceptualized the study, developed the methodology, wrote, edited, and reviewed the manuscript.

C Hilton: Contributed to methodology, edited, and reviewed the manuscript.

P Hull: Contributed to methodology, edited, and reviewed the manuscript.

J Kassam: Conceptualized the study, contributed to methodology, edited, and reviewed the manuscript.

C Maturana: Trial coordination activities, contributed to methodology, wrote, edited and reviewed the manuscript.

C McDaid: Conceptualized the study, developed the methodology, wrote, edited and reviewed the manuscript.

J Roche Contributed to statistical aspects of methodology, edited and reviewed the manuscript

D Sivapathasuntharam: Contributed to methodology, edited and reviewed the manuscript.

D Torgerson: Conceptualized the study, developed the methodology, and reviewed the manuscript.

All authors have approved the submitted version of the manuscript.

All authors agree both to be personally accountable for their own contributions and to ensure that any questions related to the accuracy or integrity of any part of the work even ones in which the author was not personally involved, are appropriately investigated, resolved and the resolution documented in the literature.

**Funding**

The study is funded by the National Institute for Health Research Health Technology Assessment Programme (NIHR HTA) project number 16/167/57. The views expressed therein are those of the authors and not necessarily reflect those of the NIHR or the Department of Health and Social Care. The detailed planned study design was subject to external peer review on behalf of the funder and the protocol, amendments and outputs were also agreed with the funder.

**Availability of data and materials**

Permission to access source data by study staff and for regulatory and audit purposes will be sought via the patient consent form, with an explicit explanation in the information sheet and consent discussion. External requests for data following completion of planned analysis and dissemination will be notified to the CI and Sponsor for consideration and approval before seeking confirmation from the funding body. Any data will be anonymized before secure transfer.

**Ethics approval and consent to participate**

As the study is led from England, approval from a REC in England was sought and this study has been reviewed and given favourable opinion by London - Harrow REC (Ref: 19/LO/0555). The HRA has also given governance approval. In addition, the study was reviewed and given approval by Scotland A REC (REF 21/SS/0002), which is specifically related to the inclusion of patients who lack capacity to consent in Scotland.

Written, informed consent to participate will be obtained from all participants with capacity. Participants have the right to withdraw from the study at any time and for any reason, and all participants are made aware that withdrawal will not affect their routine care. The study will include patients who lack capacity, and as appropriate, consultee declaration will be sought from a personal or nominated consultee (in England, Wales, and Northern Ireland) or consent will be sought from a Guardian, Welfare Attorney or nearest relative (in Scotland). The process for seeking consultee declaration for patients lacking capacity in England, Wales and Northern Ireland has been approved by the Research Ethics Committee in England and will be in accordance with the Mental Capacity Act 2005 for England and Wales and in accordance with the Mental Capacity Act (NI) 2016 for Northern Ireland. The process for seeking consent for patients who lack capacity in Scotland will be in accordance with the Adults with Incapacity Act (Scotland) 2000 and approved by the Research Ethics Committee in Scotland. The Mental Capacity Act 2005, the Mental Capacity Act (NI) 2016 and the Adults with Incapacity Act (Scotland) 2000 establish a framework for the protection of the rights of people who lack the capacity to decide themselves. They are designed to ensure that the interests and rights of people who lack capacity are protected and that their current and previously expressed wishes are respected.

**Consent for publication**

Not applicable since there are no identifying images or other personal or clinical details of participants presented. Informed consent materials are available from the corresponding author.

**Competing interests**

The authors declare that they have no competing interests except for:

P Bates holds educational contracts with Johnson and Johnson and Zimmer Biomet, for delivering teaching, visitations and webinars. He is one of the design surgeons for a pelvic plating system, ‘*Phoenix’* manufactured by ITS. Importantly, this plating system is not used in the treatment of fragility LC-1 pelvic fractures. He is a senior lecturer at QMUL, in Orthopaedic Trauma Sciences.

C McDaid is a member of the NIHR HTA & EME Journal Editorial Board and has received funding from the British Orthopaedic Association to support grant applications.

C Hewitt is a member of the NIHR HTA commissioning committee (2015-present) and Deputy Chair (2019-present).

These associations and grants have not in any way influenced contribution to this study.

**References:**

1. Andrich S, Haastert B, Neuhaus E, Neidert K, Arend W, Ohmann C, et al. Epidemiology of Pelvic Fractures in Germany: Considerably High Incidence Rates among Older People. PLoS One. 2015;10(9):e0139078.

2. Hill RM, Robinson CM, Keating JF. Fractures of the pubic rami. Epidemiology and five-year survival. J Bone Joint Surg Br. 2001;83(8):1141-4.

3. Studer P, Suhm N, Zappe B, Bless N, Jakob M. Pubic rami fractures in the elderly--a neglected injury? Swiss Med Wkly. 2013;143:w13859.

4. Farouk O, El-Adly W, Khalefa YE. Late fixation of vertically unstable type-C pelvic fractures: difficulties and surgical solutions. European Orthopaedics and Traumatology. 2015;6(1):15-22.

5. Soles GL, Ferguson TA. Fragility fractures of the pelvis. Curr Rev Musculoskelet Med. 2012;5(3):222-8.

6. Greenleaf JE, Kozlowski S. Physiological consequences of reduced physical activity during bed rest. Exerc Sport Sci Rev. 1982;10:84-119.

7. Koval KJ, Aharonoff GB, Schwartz MC, Alpert S, Cohen G, McShinawy A, et al. Pubic rami fracture: a benign pelvic injury? J Orthop Trauma. 1997;11(1):7-9.

8. Taillandier J, Langue F, Alemanni M, Taillandier-Heriche E. Mortality and functional outcomes of pelvic insufficiency fractures in older patients. Joint Bone Spine. 2003;70(4):287-9.

9. Breuil V, Roux CH, Testa J, Albert C, Chassang M, Brocq O, et al. Outcome of osteoporotic pelvic fractures: an underestimated severity. Survey of 60 cases. Joint Bone Spine. 2008;75(5):585-8.

10. Uchida K, Kokubo Y, Yayama T, Nakajima H, Miyazaki T, Negoro K, et al. Fracture of the pelvic ring: A retrospective review of 224 patients treated at a single institution. European Journal of Orthopaedic Surgery & Traumatology. 2011;21:251-7.

11. Lefaivre KA, Slobogean GP, Ngai JT, Broekhuyse HM, O'Brien PJ. What outcomes are important for patients after pelvic trauma? Subjective responses and psychometric analysis of three published pelvic-specific outcome instruments. J Orthop Trauma. 2014;28(1):23-7.

12. Marrinan S, Pearce MS, Jiang XY, Waters S, Shanshal Y. Admission for osteoporotic pelvic fractures and predictors of length of hospital stay, mortality and loss of independence. Age Ageing. 2015;44(2):258-61.

13. Clement ND, Court-Brown CM. Elderly pelvic fractures: the incidence is increasing and patient demographics can be used to predict the outcome. Eur J Orthop Surg Traumatol. 2014;24(8):1431-7.

14. Kannus P, Palvanen M, Niemi S, Parkkari J, Järvinen M. Epidemiology of osteoporotic pelvic fractures in elderly people in Finland: sharp increase in 1970-1997 and alarming projections for the new millennium. Osteoporos Int. 2000;11(5):443-8.

15. Aprato A, Joeris A, Tosto F, Kalampoki V, Stucchi A, Massè A. Direct and indirect costs of surgically treated pelvic fractures. Arch Orthop Trauma Surg. 2016;136(3):325-30.

16. Krappinger D, Struve P, Schmid R, Kroesslhuber J, Blauth M. Fractures of the pubic rami: a retrospective review of 534 cases. Arch Orthop Trauma Surg. 2009;129(12):1685-90.

17. Scheyerer MJ, Osterhoff G, Wehrle S, Wanner GA, Simmen HP, Werner CM. Detection of posterior pelvic injuries in fractures of the pubic rami. Injury. 2012;43(8):1326-9.

18. Fractures (complex): assessment and management. NICE guideline Published: 17 February 2016 www.nice.org.uk/guidance/ng37

19. The Management of Patients with Pelvic Fractures. BOA Standards for Trauma and Orthopaedics (BOASTs) 2012 [Available from: <https://www.boa.ac.uk/publications/boa-standards-trauma-boasts/>.]

20. Vaidya R, Colen R, Vigdorchik J, Tonnos F, Sethi A. Treatment of unstable pelvic ring injuries with an internal anterior fixator and posterior fixation: initial clinical series. J Orthop Trauma. 2012;26(1):1-8.

21. Vaidya R, Martin AJ, Roth M, Nasr K, Gheraibeh P, Tonnos F. INFIX versus plating for pelvic fractures with disruption of the symphysis pubis. Int Orthop. 2017;41(8):1671-8.

22. Dahill M, McArthur J, Roberts GL, Acharya MR, Ward AJ, Chesser TJS. The use of an anterior pelvic internal fixator to treat disruptions of the anterior pelvic ring: a report of technique, indications and complications. Bone Joint J. 2017 Sep;99-b(9):1232-6 doi: 10.1302/0301-620X.99B9. BJJ-2016-1025.R2. PMID: 28860405..

23. Booth A, Ingoe HMA, Northgraves M, Coleman E, Harden M, Kassam J, et al. Effectiveness of surgical fixation for lateral compression type one (LC-1) fragility fractures of the pelvis: a systematic review. BMJ Open. 2019;9(5):e024737.

24. Fang C, Alabdulrahman H, Pape HC. Complications after percutaneous internal fixator for anterior pelvic ring injuries. Int Orthop. 2017;41(9):1785-90.

25. lobogean GP, Gaski GE, Nascone J, Sciadini MF, Natoli RM, Manson TT, Lebrun C, McKinley T, Virkus WW, Sorkin AT, Brown K, Howe A, Rudnicki J, Enobun B, O'Hara NN, Gill J, O'Toole RV. A Prospective Clinical Trial Comparing Surgical Fixation Versus Nonoperative Management of Minimally Displaced Complete Lateral Compression Pelvis Fractures. J Orthop Trauma. 2021 Nov 1;35(11):592-598. doi: 10.1097/BOT.0000000000002088. PMID: 33993178..

26. Parsons N, Griffin XL, Achten J, Costa ML. Outcome assessment after hip fracture: is EQ-5D the answer? Bone Joint Res. 2014;3(3):69-75.

27. EuroQol Research Foundation. EQ-5D-5L User Guide, 2019. Available from: https://euroqol.org/publications/user-guides.

28. PROMIS Health Organization. *PROMIS (Patient Reported Outcome Measurement Information System)*. URL: <https://www.promishealth.org/healthmeasures/> (Last Accessed 23/10/2021).

29. Brooks D, Davis AM, Naglie G. Validity of 3 physical performance measures in inpatient geriatric rehabilitation. Arch Phys Med Rehabil. 2006;87(1):105-10.

30. Steffen TM, Hacker TA, Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and gait speeds. Phys Ther. 2002;82(2):128-37.

31. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S240-52.

32. Pendlebury ST, Klaus SP, Mather M, de Brito M, Wharton RM. Routine cognitive screening in older patients admitted to acute medicine: abbreviated mental test score (AMTS) and subjective memory complaint versus Montreal Cognitive Assessment and IQCODE. Age Ageing. 2015;44(6):1000-5.

33. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972;1(4):233-8.

34. Bellelli G, Morandi A, Davis DH, Mazzola P, Turco R, Gentile S, et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age Ageing. 2014;43(4):496-502.

35. Hendry K, Quinn TJ, Evans J, Scortichini V, Miller H, Burns J, et al. Evaluation of delirium screening tools in geriatric medical inpatients: a diagnostic test accuracy study. Age Ageing. 2016;45(6):832-7.

36. Yang Y, Zhao X, Dong T, Yang Z, Zhang Q, Zhang Y. Risk factors for postoperative delirium following hip fracture repair in elderly patients: a systematic review and meta-analysis. Aging Clin Exp Res. 2017;29(2):115-26.

37. Robinson TN, Eiseman B. Postoperative delirium in the elderly: diagnosis and management. Clin Interv Aging. 2008;3(2):351-5.

38. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309-32.

39. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523-32.

40. Adachi JD, Adami S, Gehlbach S, Anderson FA, Jr., Boonen S, Chapurlat RD, et al. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc. 2010;85(9):806-13.

41. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100-7.

42. Ashby R, Turner G, Cross B, Mitchell N, Torgerson D. A randomized trial of electronic reminders showed a reduction in the time to respond to postal questionnaires. J Clin Epidemiol. 2011;64(2):208-12.

43. Mitchell N, Hewitt CE, Lenaghan E, Platt E, Shepstone L, Torgerson DJ. Prior notification of trial participants by newsletter increased response rates: a randomized controlled trial. J Clin Epidemiol. 2012;65(12):1348-52.

44. National Institute for Health and Care Excellence (NICE). Position statement on use of the EQ-5D-5L value set for England 2019 [Available from: <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l>.

45. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess. 1999;3(10):1-152.

46. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics. 2014;32(12):1157-70.

47. Lomas J, Claxton K, Martin S, Soares M. Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. Value Health. 2018;21(3):266-75.

48. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1-503, v-vi.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

|  |  |  |  |
| --- | --- | --- | --- |
| Section/item | Item No | Description | Addressed on page number |
| **Administrative information** |  |
| Title | 1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | Page 1 and 3 |
| Trial registration | 2a | Trial identifier and registry name. If not yet registered, name of intended registry | Page 2 and 3 |
| 2b | All items from the World Health Organization Trial Registration Data Set | Page 3 |
| Protocol version | 3 | Date and version identifier | Page 3  |
| Funding | 4 | Sources and types of financial, material, and other support | Page 3 and 39 |
| Roles and responsibilities | 5a | Names, affiliations, and roles of protocol contributors | Page 3-4 |
| 5b | Name and contact information for the trial sponsor | Page 4 |
|  | 5c | Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities | Page 4 |
|  | 5d | Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) | Page 30-31 |
| Introduction |  |  |  |
| Background and rationale | 6a | Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention | Page 4-10 |
|  | 6b | Explanation for choice of comparators | Page 6-8 |
| Objectives | 7 | Specific objectives or hypotheses | Page 10 |
| Trial design | 8 | Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) | Page 10-11 |
| Methods: Participants, interventions, and outcomes |  |
| Study setting | 9 | Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained | Page 11-12 |
| Eligibility criteria | 10 | Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) | Page 12-13 |
| Interventions | 11a | Interventions for each group with sufficient detail to allow replication, including how and when they will be administered | Page 13-15 |
| 11b | Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) | Page 14-15 |
| 11c | Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) | NA |
| 11d | Relevant concomitant care and interventions that are permitted or prohibited during the trial | Page 14-15 |
| Outcomes | 12 | Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended | Page 15-20 |
| Participant timeline | 13 | Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) | Page 20-21 |
| Sample size | 14 | Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations | Page 21 |
| Recruitment | 15 | Strategies for achieving adequate participant enrolment to reach target sample size | Page 21-22 |
| **Methods: Assignment of interventions (for controlled trials)** |  |
| Allocation: |  |  |  |
| Sequence generation | 16a | Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions | Page 22 |
| Allocation concealment mechanism | 16b | Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned | Page 22 |
| Implementation | 16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions | Page 22 |
| Blinding (masking) | 17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how | Page 22-23 |
|  | 17b | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial | NA |
| **Methods: Data collection, management, and analysis** |  |
| Data collection methods | 18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol | Page 23-24 |
|  | 18b | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols | Page 23-24 |
| Data management | 19 | Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol | Page 24 |
| Statistical methods | 20a | Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol | Page 25-28 |
|  | 20b | Methods for any additional analyses (eg, subgroup and adjusted analyses) | Page 29 |
|  | 20c | Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) | Page 29-30 |
| **Methods: Monitoring** |  |
| Data monitoring | 21a | Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed | Page 31-32 |
|  | 21b | Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial | Page 28-29 |
| Harms | 22 | Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct | Page 32-33 |
| Auditing | 23 | Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor | Page 33 |
| Ethics and dissemination |  |
| Research ethics approval | 24 | Plans for seeking research ethics committee/institutional review board (REC/IRB) approval | Page 39-40 |
| Protocol amendments | 25 | Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) | Page 31-32 |
| Consent or assent | 26a | Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) | Page 13 |
|  | 26b | Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable | Page 13 |
| Confidentiality | 27 | How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial | Page 24-25 |
| Declaration of interests | 28 | Financial and other competing interests for principal investigators for the overall trial and each study site | Page 40-41 |
| Access to data | 29 | Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators | Page 39 |
| Ancillary and post-trial care | 30 | Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation | Page 15 |
| Dissemination policy | 31a | Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions | Page 33-34 |
|  | 31b | Authorship eligibility guidelines and any intended use of professional writers | Page 37-38 |
|  | 31c | Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code | Page 30 |
| Appendices |  |  |  |
| Informed consent materials | 32 | Model consent form and other related documentation given to participants and authorised surrogates | NA |
| Biological specimens | 33 | Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable | NA |

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “[Attribution-NonCommercial-NoDerivs 3.0 Unported](http://www.creativecommons.org/licenses/by-nc-nd/3.0/)” license.